Ferumoxytol: a Silver Lining in the Treatment of Anemia of Chronic Kidney Disease or Another Dark Cloud?

Overview

Journal J Blood Med

Publisher Dove Medical Press

Specialty Hematology

Date 2012 Sep 14

PMID 22973119

Citations 22

Authors

Amy Barton Pai

Adinoyi O Garba

Affiliations

Soon will be listed here.

Abstract

Intravenous iron therapy is pivotal in the treatment of anemia of chronic kidney disease to optimize the response of hemoglobin to erythropoiesis-stimulating agents. Intravenous iron use in patients with chronic kidney disease is on the rise. Recent clinical trial data prompting safety concerns regarding the use of erythropoiesis-stimulating agents has stimulated new US Food and Drug Administration label changes and restrictions for these agents, and has encouraged more aggressive use of intravenous iron. The currently available intravenous iron products differ with regard to the stability of the iron-carbohydrate complex and potential to induce hypersensitivity reactions. Ferumoxytol is a newer large molecular weight intravenous iron formulation that is a colloidal iron oxide nanoparticle suspension coated with polyglucose sorbitol carboxymethyl ether. Ferumoxytol has robust iron-carbohydrate complex stability with minimal dissociation or appearance of free iron in the serum, allowing the drug to be given in relatively large doses with a rapid rate of administration. Clinical trials have demonstrated the superior efficacy of ferumoxytol versus oral iron with minimal adverse effects. However, recent postmarketing data have demonstrated a risk of hypersensitivity that has prompted new changes to the product information mandated by the Food and Drug Administration. Additionally, the long-term safety of this agent has not been evaluated, and its place in the treatment of anemia of chronic kidney disease has not been fully elucidated.

Citing Articles

Brand ferumoxytol vs. generic ferumoxytol comparison across two dosing regimens: a cardiac MRI image quality study.

Dasi A, Kring D, Selvaraj B, Morgan P, Gerity C, Morgan E Pediatr Radiol. 2023; 53(13):2622-2632.

PMID: 37837456 DOI: 10.1007/s00247-023-05778-4.

Ferroptosis in Haematological Malignancies and Associated Therapeutic Nanotechnologies.

Mynott R, Habib A, Best O, Wallington-Gates C Int J Mol Sci. 2023; 24(8).

PMID: 37108836 PMC: 10146166. DOI: 10.3390/ijms24087661.

Iron Oxide Nanoparticles in Bioimaging - An Immune Perspective.

Geppert M, Himly M Front Immunol. 2021; 12:688927.

PMID: 34211476 PMC: 8239972. DOI: 10.3389/fimmu.2021.688927.

Safety issues related to intravenous contrast agent use in magnetic resonance imaging.

Ponrartana S, Moore M, Chan S, Victoria T, Dillman J, Chavhan G Pediatr Radiol. 2021; 51(5):736-747.

PMID: 33871726 DOI: 10.1007/s00247-020-04896-7.

Wearable Fixation Device for a Magnetically Controllable Therapeutic Agent Carrier: Application to Cartilage Repair.

Lee K, Go G, Yoo A, Kang B, Choi E, Park J Pharmaceutics. 2020; 12(6).

PMID: 32604748 PMC: 7355457. DOI: 10.3390/pharmaceutics12060593.

References

Balakrishnan V, Rao M, Kausz A, Brenner L, Pereira B, Frigo T . Physicochemical properties of ferumoxytol, a new intravenous iron preparation. Eur J Clin Invest. 2009; 39(6):489-96. DOI: 10.1111/j.1365-2362.2009.02130.x. View

Pai A, Boyd A, McQuade C, Harford A, Norenberg J, Zager P . Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis. Pharmacotherapy. 2007; 27(3):343-50. DOI: 10.1592/phco.27.3.343. View

Landry R, Jacobs P, Davis R, Shenouda M, Bolton W . Pharmacokinetic study of ferumoxytol: a new iron replacement therapy in normal subjects and hemodialysis patients. Am J Nephrol. 2005; 25(4):400-10. DOI: 10.1159/000087212. View

Seligman P, Dahl N, Strobos J, Kimko H, Schleicher R, Jones M . Single-dose pharmacokinetics of sodium ferric gluconate complex in iron-deficient subjects. Pharmacotherapy. 2004; 24(5):574-83. DOI: 10.1592/phco.24.6.574.34750. View

McLachlan S, Morris M, LUCAS M, Fisco R, Eakins M, Fowler D . Phase I clinical evaluation of a new iron oxide MR contrast agent. J Magn Reson Imaging. 1994; 4(3):301-7. DOI: 10.1002/jmri.1880040313. View

Gilbertson D, Ebben J, Foley R, Weinhandl E, Bradbury B, Collins A . Hemoglobin level variability: associations with mortality. Clin J Am Soc Nephrol. 2007; 3(1):133-8. PMC: 2390986. DOI: 10.2215/CJN.01610407. View

Toblli J, Cao G, Oliveri L, Angerosa M . Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model. Arzneimittelforschung. 2011; 61(7):399-410. DOI: 10.1055/s-0031-1296218. View

Agarwal R, Leehey D, Olsen S, Dahl N . Proteinuria induced by parenteral iron in chronic kidney disease--a comparative randomized controlled trial. Clin J Am Soc Nephrol. 2010; 6(1):114-21. PMC: 3022232. DOI: 10.2215/CJN.06020710. View

Robinson B, Fuller D, Bieber B, Turenne M, Pisoni R . The DOPPS Practice Monitor for US dialysis care: trends through April 2011. Am J Kidney Dis. 2011; 59(2):309-12. DOI: 10.1053/j.ajkd.2011.11.005. View

10.

Ford B, Eby C, Scott M, Coyne D . Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients. Kidney Int. 2010; 78(8):769-73. DOI: 10.1038/ki.2010.254. View

11.

Jomova K, Valko M . Importance of iron chelation in free radical-induced oxidative stress and human disease. Curr Pharm Des. 2011; 17(31):3460-73. DOI: 10.2174/138161211798072463. View

12.

Tsuchiya K, Nitta N, Sonoda A, Nitta-Seko A, Ohta S, Otani H . Histological study of the biodynamics of iron oxide nanoparticles with different diameters. Int J Nanomedicine. 2011; 6:1587-94. PMC: 3152477. DOI: 10.2147/IJN.S22189. View

13.

Jahn M, Andreasen H, Futterer S, Nawroth T, Schunemann V, Kolb U . A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm. 2011; 78(3):480-91. DOI: 10.1016/j.ejpb.2011.03.016. View

14.

Singh A, Patel T, Hertel J, Bernardo M, Kausz A, Brenner L . Safety of ferumoxytol in patients with anemia and CKD. Am J Kidney Dis. 2008; 52(5):907-15. DOI: 10.1053/j.ajkd.2008.08.001. View

15.

Bailie G . Comparison of rates of reported adverse events associated with i.v. iron products in the United States. Am J Health Syst Pharm. 2012; 69(4):310-20. DOI: 10.2146/ajhp110262. View

16.

Del Vecchio L, Locatelli F, Carini M . What we know about oxidative stress in patients with chronic kidney disease on dialysis--clinical effects, potential treatment, and prevention. Semin Dial. 2011; 24(1):56-64. DOI: 10.1111/j.1525-139X.2010.00819.x. View

17.

Ternes N, Scheiber-Mojdehkar B, Landgraf G, Goldenberg H, Sturm B . Iron availability and complex stability of iron hydroxyethyl starch and iron dextran a comparative in vitro study with liver cells and macrophages. Nephrol Dial Transplant. 2007; 22(10):2824-30. DOI: 10.1093/ndt/gfm315. View

18.

Singh A, Szczech L, Tang K, Barnhart H, Sapp S, Wolfson M . Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355(20):2085-98. DOI: 10.1056/NEJMoa065485. View

19.

Simon G, Vopelius-Feldt J, Fu Y, Schlegel J, Pinotek G, Wendland M . Ultrasmall supraparamagnetic iron oxide-enhanced magnetic resonance imaging of antigen-induced arthritis: a comparative study between SHU 555 C, ferumoxtran-10, and ferumoxytol. Invest Radiol. 2005; 41(1):45-51. DOI: 10.1097/01.rli.0000191367.61306.83. View

20.

Provenzano R, Schiller B, Rao M, Coyne D, Brenner L, Pereira B . Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol. 2009; 4(2):386-93. PMC: 2637590. DOI: 10.2215/CJN.02840608. View